AiCure and IMA Group Partner in Trial Recruitment and Engagement
AiCure and IMA have announced a partnership aiming to gain a widespread understanding of patient behavior and drug compliance outside of a clinical trial setting. With a database of over 300,000 potential subjects, IMA will roll out AiCure's Patient Connect, to study participants, offering patients support to manage their existing treatment at home. This data will ultimately give sponsors access to a diverse pool of patients with known adherence patterns across therapeutic areas that could be recruited for upcoming trials.
As part of a 30-day program, participating patients will use AiCure's solution via their smartphone each time they dose, which uses computer vision and AI to confirm adherent dosing behavior in a HIPAA compliant manner. Patient Connect can also aggregate ePRO and digital biomarker data to detect subtle changes in a patient's condition. Additionally, patients will gain access to communication tools to connect directly to a clinician for further support.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
